The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass $60 billion from around $45 billion in FY21, according to a report.
The domestic pharma industry globally ranks third in terms of volume and 13th in value terms, which is primarily because of the predominance of generics.
As per the report, the industry is expected to grow at about 11 per cent in the next two years to cross the $60- billion-mark in FY24 from $45 billion in FY21.
The report expects this faster growth to be driven by the ability of the domestic industry to leverage the opportunities arising from the expiry of the many patented drugs across the globe, ebbing of regulatory risks, adoption of various de-risk strategies from China dependency for key raw materials, increasing PE investments, and strong fundamentals of the industry
The domestic industry was $18 billion in FY17, and since then, it has grown at 4.5 per cent per annum and touched $21 billion in FY21. Pharma exports were $17 billion in FY17 and reached $24 billion in FY21, clipping at 10 per cent annually. In FY21, exports grew 18 per cent on the back of pandemic-related drugs. Despite this, the share of exports to overall income has come from 52 per cent in FY17 to 47 per cent in FY21, the report said.
Over the next five years, the patented drugs worth $240 billion will go off-patents globally. This provides a large opportunity for domestic generic formulation companies who are already developing the generic versions of these IDMA Bulletin LII (32) 22 to 30 August 2021 27 patented drugs to cash in on early and are expected to reap $5-6 billion of additional income.
The focus on generics has the domestic country enjoying significant cost advantages in terms of production, R&D and clinical trials over the developed market to the tune of 50, 87 and 90 per cent, respectively
The country’s share in total ANDA approvals has increased from around 40 per cent in 2020 to around 44 per cent as of June 2021. It was 36 per cent in 2017 as it has the largest number of USFDA-compliant pharma plants outside of the US.
The report also expects the R&D expenditure by the domestic pharma companies to remain at about 8 per cent of the total sales for FY23.
